FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Metabolic

Retatrutide 5mg

5mg triple-agonist research peptide

From€69.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-RET-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Retatrutide Fascinates Researchers

Retatrutide — development designation LY3437943 — represents the current frontier of incretin receptor pharmacology: a single peptide molecule engineered to simultaneously activate three distinct G protein-coupled receptors. Its triple agonist architecture distinguishes it from all earlier compounds in the incretin class and positions it as among the most potent metabolic research tools currently under investigation.

The Triple-Receptor Paradigm

The incretin system — comprising GLP-1 and GIP, secreted from intestinal L- and K-cells respectively in response to nutrient ingestion — has been pharmacologically validated across two decades of drug development. GLP-1 receptor agonists act on beta-cell insulin secretion, gastric emptying, and hypothalamic appetite circuits; GIPR agonism adds complementary effects on adipose insulin sensitivity and bone metabolism. Retatrutide extends this framework by adding glucagon receptor (GCGR) agonism as a third simultaneous input — a receptor historically associated with hyperglycaemia risk when activated alone, but which drives potent hepatic fatty acid oxidation and thermogenic energy expenditure when balanced against GLP-1 and GIP activity. The result is a single molecule that engages three distinct G protein-coupled receptor signalling cascades concurrently, enabling the study of multi-receptor metabolic biology that cannot be dissected using earlier single- or dual-agonist tools.

Clinical Evidence

The Phase 2 randomised controlled trial published by Jastreboff and colleagues in the New England Journal of Medicine (2023) provided the most comprehensive pharmacological dataset available for any triple incretin receptor agonist. At the highest tested dose, participants achieved mean weight reductions of approximately 17.5% at 24 weeks, extending to 24.2% by 48 weeks — figures substantially exceeding those reported for semaglutide or tirzepatide in comparable trial designs. Secondary endpoints documented significant reductions in waist circumference, visceral fat fraction by MRI, HbA1c, triglycerides, and hepatic fat content, offering a multi-domain view of the compound's metabolic pharmacodynamics across adipose, glycaemic, and hepatic compartments.

The preceding Phase 1 study by Nahra and colleagues (2021, Diabetes Care) established the human pharmacokinetic and pharmacodynamic profile, confirming dose-dependent reductions in postprandial glucose and body weight with a once-weekly subcutaneous dosing schedule and an adverse event pattern consistent with GLP-1 class effects.

Research Landscape

As a triple receptor agonist with precisely characterised pharmacology, retatrutide is a valuable tool for dissecting the relative contributions of GLP-1R, GIPR, and GCGR signalling to metabolic phenotypes in preclinical models. Comparative studies using selective receptor antagonists or receptor-knockout mouse lines alongside retatrutide administration can help deconvolve individual receptor contributions from the composite pharmacological signal — an important methodological approach for understanding multi-receptor incretin biology. Growing interest in MASLD/NASH research models is further supported by Phase 2 hepatic fat reduction data, providing a compelling rationale for preclinical investigation of GCGR-mediated hepatic lipid flux.

This content is for informational purposes only and reflects the state of clinical and preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for Retatrutide 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Retatrutide investigation.

[01]
Jastreboff AM, Kaplan LM, Frías JP, et al. (2023) — New England Journal of Medicine

“Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial”

Pivotal Phase 2 randomised controlled trial of retatrutide in adults with obesity. At the highest dose, 24-week mean weight reduction reached 17.5%, with 48-week data showing 24.2% reduction — figures substantially exceeding prior generation incretin agonists. The trial also documented significant improvements in cardiometabolic markers including HbA1c, triglycerides, and hepatic fat fraction.

View on PubMed
[02]
Coskun T, Urva S, Roell WC, et al. (2022) — Cell Metabolism

“LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss”

Preclinical characterisation study establishing retatrutide's pharmacological profile as a balanced triple agonist. In diet-induced obese and diabetic rodent models, LY3437943 produced superior reductions in body weight, food intake, and glycaemic markers compared to dual-agonist comparators, validating the multi-receptor pharmacological concept and defining receptor binding affinities and signalling characteristics.

View on PubMed
[03]
Nahra R, Wang T, Gjessing PF, et al. (2021) — Diabetes Care

“Effects of LY3437943 on glycemia and body weight in type 2 diabetes: a Phase 1 study”

First-in-human Phase 1 safety and pharmacodynamics study of retatrutide in participants with type 2 diabetes. Single and multiple ascending doses demonstrated dose-dependent reductions in postprandial glucose and body weight, with a pharmacokinetic profile supporting once-weekly subcutaneous dosing and an adverse event pattern consistent with GLP-1 class effects.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Retatrutide.

Same Category

Similar Compounds

Other Metabolic research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.